what’s new

…there’s no doubt in my mind that the use of top-notch technology and assays has helped our hospital achieve and maintain such a high level of performance.”

Richard Lent, Ph.D.
Core Lab Director & Chief
of Clinical Biochemistry
NewYork-Presbyterian Hospital
New York, NY

ebia Electrophoresis is 100% focused on the science of electrophoresis. At least 10% of the annual budget is dedicated to research and development resulting in a continuous stream of new and innovative electrophoresis product introductions. What’s new at Sebia?

Expanding line of Capillary Electrophoresis (CE) Technology:

The MINICAP instrument represents the latest evolution in Sebia’s innovative line of CE technology, which also includes the CAPILLARYS™ 2. The MINICAP offers sophisticated, completely walk-away automation with a small instrument footprint.

News from the FDA:

MINICAP
Sebia has received clearance from the Food and Drug Administration (FDA) to market the MINICAP Protein 6 assay – for the separation and quantitation of the six major serum protein fractions. Separation and direct detection of serum proteins take place with the newly released MINICAP instrument

CAPILLARYS 2
Sebia has received clearance from the FDA to market the CAPILLARYS™ Hemoglobin assay. Utilized with the CAPILLARYS 2 instrument, CAPILLARYS Hemoglobin aids in the diagnosis of hemoglobinopathies and thalassemias and is designed to separate, detect, and quantify normal hemoglobins and hemoglobin variants.

Sebia has received clearance from the FDA to market the CAPILLARYS Urine kit, which allows for the separation of urine proteins by capillary electrophoresis technology.

View a video introduction to CAPILLARYS 2 technology.

HYDRASYS
Sebia has received FDA clearance to market the HYDRAGEL® A1AT Isofocusing kit designed for the qualitative detection and identification of different phenotypes of A1AT. This marks the first FDA cleared kit for A1AT Phenotyping. Phenotyping results, in conjunction with clinical findings and other laboratory assays, aid in the diagnosis of A1AT deficiency – the most common genetic cause of liver disease in children. A set of three FDA cleared A1AT Controls are also available.

Business Partnerships:

We would like to welcome each Beckman-Coulter electrophoresis customer to Sebia Electrophoresis. To help support this transition process we have established a separate email address (BC@Sebia-usa.com) for questions regarding the Beckman-Coulter and Sebia collaboration or you could call us directly at 1-800-835-6497 and ask for the Sebia Transition Team for Paragon Products. Welcome to the Sebia family and we look forward to working with you and your laboratory!

 
CAPILLARYS™ 2 Product Details CAPILLARYS™ 2 Test Menu